Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Mid-range Performer
1009.7500 4.15 (0.41%)
NSE Apr 07, 2026 11:23 AM
Volume: 10,968
 

logo
Alivus Life Sciences Ltd.
27 Jan 2023
1009.75
0.41%
buy
by BOB Capital Markets Ltd.
Target: 585
BOB Capital Markets Ltd.
Q3 revenue up 6% QoQ to Rs 5.4bn supported by sequential recovery in API business to parent and PLI benefits
 
Alivus Life Sciences Ltd. is trading above all available SMAs
More from Alivus Life Sciences Ltd.
Recommended
Market trades lower, Godrej Consumer Products projects double-digit revenue growth in Q4FY26
Trendlyne Marketwatch | 07 Apr 2026, 11:02AM
IPO pipeline stays active, while post-listing performance remains subdued
| 06 Apr 2026, 05:47PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
| 27 Jul 2021